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The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-
Cyclam Complex on Cancer Stem Cells 
Paul B. Cressey, Arvin Eskandari, Peter M. Bruno, Chunxin Lu, Michael T. Hemann, and 
Kogularamanan Suntharalingam* 
Abstract: We report the cancer stem cell (CSC) potency of a novel 
cobalt(III)-cyclam complex, 1 bearing the nonsteroidal anti-
inflammatory drug, naproxen. The cobalt(III)-cyclam complex, 1 
displays selective potency for breast CSC-enriched HMLER-shEcad 
cells over breast CSC-depleted HMLER cells. Additionally, 1 inhibits 
the formation of three-dimensional tumor-like mammospheres, and 
reduces their viability to a greater extent than clinically used breast 
cancer drugs; vinorelbine, cisplatin, and paclitaxel. The 
mammosphere-potency of 1 was enhanced in hypoxia-mimicking 
conditions. Detailed mechanistic studies revealed that DNA damage 
and cyclooxygenase-2 (COX-2) inhibition contribute to the cytotoxic 
mechanism of action of 1. To the best of our knowledge, 1 is the first 
cobalt-containing compound to show selective potency for CSCs 
over bulk cancer cells. 
There is mounting evidence linking fatal incidences of 
cancer relapse with cancer stem cells (CSCs), a 
subpopulation of cancer cells with the ability to self-renew, 
differentiate, and initiate tumor growth.[1] Due to their 
remarkable stem cell-like properties, CSCs are thought to 
be key drivers in tumor progression and therapeutic 
resistance.[2] Surgery in combination with chemotherapy 
and radiotherapy effectively reduces tumor mass by 
removing non-tumorigenic, bulk cancer cells, but they are 
unable to eliminate CSCs.[3] CSCs remain largely 
untouched by current therapeutic regimens, and can initiate 
tumor regrowth. Therefore to improve clinical outcomes, 
treatments must have the ability to kill all forms of cancer 
cells, including CSCs. Although several kinks in the CSC 
armoury have been identified, such as deregulated 
signalling pathways, overactive organelles, and cell surface 
markers,[4] there is still no clinically approved drug 
(chemical or biological) that can selectively remove CSCs.  
 Cytotoxic compounds capable of accumulating and 
undergoing activation in microenvironments (niches) 
supporting CSCs can potentially kill CSCs specifically.[4a,5] 
The CSC microenvironment is thought to be hypoxic, and a 
clear link between hypoxia inducible factors (HIFs), 
particularly HIF1α and HIF2α, and CSC regulation is now 
emerging.[6] Recent studies indicate that HIF1α and HIF2α 
are highly expressed in breast, glioma, and neuroblastoma 
CSCs, and play pivotal roles in CSC self-renewal.[7] Here, 
we present a cobalt(III)-cyclam complex capable of 
releasing naproxen, a nonsteroidal anti-inflammatory drug 
(NSAID), under reducing conditions. Naproxen is an 
inhibitor of cyclooxygenase isoenzymes, COX-1 and COX-
2.[8] Cyclooxygenases catalyse the biosynthesis of 
prostaglandins (PGs), which are mediators in inflammatory 
reactions. The inducible isoform, COX-2 is highly expressed 
in certain CSCs and promotes stem cell renewal, 
proliferation, and radioresistance.[9] Therefore, inhibition of 
COX-2 using small molecules like NSAIDs provides an 
effective method of sensitizing CSCs to cytotoxic agents. 
We and others have recently shown that free NSAIDs and 
metal-NSAIDs conjugates can supress CSC proliferation.[10]  
 Cobalt is an essential trace element found in all animals 
and plays a crucial role in several biologically important 
processes.[11] Over the last three decades, several cobalt-
containing compounds have been investigated for their 
anticancer activity.[12] The difference in reactivity of the 
accessible oxidation states of cobalt(II and III) has enabled 
the development of cobalt(III) prodrugs that can undergo 
bioreductive activation in hypoxic regions. Several 
cobalt(III) complexes with tetradentate ligands (such as 
1,4,7,10-tetraazacyclododecane, 1,4,8,11-
tetraazacyclotetradecane, and tris(2-pyridylmethyl)amine) 
have been used to deliver therapeutic and imaging agents 
to hypoxic tumor microenvironments.[13] Despite this there 
have been no reports on the anti-CSC properties of such 
cobalt-containing compounds. Here, we combine naproxen 
with cobalt(III)-cyclam (where cyclam = 1,4,8,11-
tetraazacyclotetradecane) in an attempt to release 
naproxen in CSCs. The role of naproxen is two-fold; it 
inhibits COX-2, which is overexpressed in CSCs, and aids 
cell uptake of the cobalt moiety (due to its inherent 
lipophilicity). 
 
Scheme 1. Chemical structures of the compounds (1, 2, and naproxen) 
under investigation. 
 
 The chemical structure of the new cobalt(III)-cyclam 
complex, 1 investigated in this study is depicted in Scheme 
1. The cobalt(III)-cyclam complex, 1 was prepared by 
reacting trans-dichloro(cyclam)-cobalt(III) chloride, 2 with 
2.5 equivalents of naproxen in methanol (dried over 
Na2SO4), in the presence of silver(I) oxide. The cobalt(III)-
cyclam complex, 1 was isolated as a purple 
hexafluorophosphate salt and characterized by 1H and 13C 
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NMR, infra-red spectroscopy, mass spectrometry, and 
elemental analysis (see SI, Figure S1-2). Single crystals of 
1 suitable for X-ray diffraction studies were obtained by 
layering a DMSO solution of 1 with acetone. The X-ray 
structure of 1 is reported in the SI (Figure S3 and Table S1-
2, CCDC 148346).  
 As cobalt complexes containing tetradentate ligands 
have been widely reported to cleave DNA,[14] the DNA 
nuclease activity of 1 was investigated using agarose-gel 
electrophoresis. Upon incubation of supercoiled plasmid 
pUC19 DNA (100 ng) with 1 (0 - 15 μM in the absence of 
external reducing agents) for 16 h, a marked increase in the 
amount of nicked circular and linear DNA was observed 
(Figure S4A). Complete conversion of supercoiled to nicked 
circular and linear DNA was observed at 2 μM. The 
cobalt(III)-cyclam complex, 2 also cleaved DNA but to a 
lesser extent than 1 (Figure S4B). Naproxen (0 - 50 μM) did 
not cleave DNA under these conditions (Figure S5). In the 
presence of ascorbic acid, a cellular reductant, the 
cleavage activity of 1 increased dramatically (Figure S6A), 
suggestive of a redox-dependent mechanism of DNA 
cleavage. In contrast, 2-induced DNA cleavage was only 
marginally enhanced in the presence of ascorbic acid 
(Figure S6B). In the presence of glutathione (10-fold 
excess) 1-mediated DNA cleavage was inhibited to some 
extent (Figure S6C). This suggests that the DNA cleavage 
activity of 1 in cell-free systems is compromised by 
glutathione. To determine the oxidative mechanism by 
which 1 induces DNA cleavage, nuclease activity was 
probed in the presence of reactive oxygen species (ROS) 
scavengers (DMSO, tBuOH, KI, and NaN3) (Figure S7A). KI 
and NaN3 blocked 1-induced DNA cleavage suggesting that 
hydrogen peroxide and singlet oxygen are involved in the 
DNA cleavage process. In the absence of oxygen, 1-
mediated DNA cleavage was blocked, reinforcing the notion 
of an oxidative mechanism (Figure S7B). We propose that 1 
undergoes reduction to the corresponding cobalt(II) form by 
guanine bases in pUC19 DNA. The cobalt(II) form then 
reduces molecular oxygen (in solution) to superoxide, which 
generates hydrogen peroxide. The paramagnetic cobalt(II) 
form and the naproxen moiety could be responsible for 
singlet oxygen generation, via a photo-redox pathway in 
ambient light.[15] Cobalt complexes are also known to cleave 
DNA via hydrolytic pathways,[14a,14b] therefore the ability of 1 
to induce DNA hydrolysis was probed using the T4 DNA 
ligase assay (see SI). pUC19 DNA that had been nicked by 
1 was re-ligated by T4 DNA ligase (Figure S8), implying 
that 1 is able cleave DNA via a hydrolytic mechanism. We 
proposes that the hydrolytic mechanism involves the 
reduction of 1 to the corresponding cobalt(II) form followed 
by aquation. The aquated cobalt species could then interact 
with the phosphate backbone of DNA, and facilitate 
hydrolytic cleavage of the P–O bond.[14b,15a] Collectively, the 
agarose-gel electrophoresis data shows that 1 is able to 
cleave DNA through, both oxidative and hydrolytic 
pathways. However given our cleavage studies in the 
absence of oxygen, we should point out that the oxidative 
mechanism appears to play a more important role in 1-
induced DNA cleavage than the hydrolytic mechanism. 
 UV-Vis spectroscopy and high-resolution ESI-TOF mass 
spectrometry studies were carried out to assess the stability 
of 1 in biologically relevant solutions. In PBS and 0.9% 
NaCl (saline) solution, 1 is reasonably stable over a period 
of 24 h at 37 oC (Figure S9-10). In Tris-HCl (pH 7.4) buffer 
and 0.9% NaCl solution with a 10-fold excess of ascorbic 
acid a marked decrease in the absorption of 1 was 
observed over a period of 24 h at 37 oC (Figure S11-12). In 
0.9% NaCl solution, significant changes to the low 
wavelength bands (< 300 nm) were observed, yielding a 
UV-Vis trace reminiscent of free naproxen (Figure S13). 
ESI-TOF mass spectroscopy studies of 1 in 0.9% NaCl 
solution with 10 equivalents of ascorbic acid after 72 h 
incubation, revealed a peak corresponding to [naproxen-
H+K]- (268.7 m/z) in the negative mode (Figure S14). This 
shows that naproxen is liberated under reducing conditions, 
presumably via the reduction of the cobalt metal centre 
from Co(III) to Co(II). Reduction to Co(II) is known to 
promote total ligand substitution,[13k] which was evidenced 
by the appearance of new peaks corresponding to [cyclam]+ 
(199.9904 m/z) and [cyclam+K]+ (238.9743 m/z) in the 
positive mode of the ESI-TOF mass spectrum (Figure 
S15A-B). Peaks associated to cobalt(II)-cyclam species 
were also observed in the positive mode (Figure S15B). 
The lipophilicity of 1 was determined by measuring the 
extent to which it partitioned between octanol and water, P. 
The experimentally determined log P value for 1 was 0.67, 
indicative of hydrophobicity. The hydrophobic character of 1 
suggests that the complex should be readily internalised by 
cells. Prior to preforming cellular studies, the stability of 1 in 
mammary epithelial cell growth medium (MEGM) at 37 oC 
was established (Figure S16).  
 The CSC potency and selectivity of 1, 2, and naproxen 
was investigated using two human mammary epithelial cell 
lines, more specifically those immortalized and transformed 
by retroviral expression of SV40 large T oncogene, hTERT 
and H-rasV12 (HMLER cells), and those subsequently 
subject to E-cadherin silencing by short hairpin RNA 
interference (HMLER-shEcad cells).[16] HMLER cells 
express a stable CSC-like population of 5-8%, whereas 
HMLER-shEcad cells express a stable CSC-like population 
of ca. 90%.[16] The cytotoxicity was determined using the 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay. The IC50 values (concentration required to 
reduce cell viability by 50%) were calculated from dose-
response curves (Figure S17-18) and are shown in Table 1. 
Salinomycin, a breast CSC-specific compound identified 
from a high-through-put screen involving 16,000 
compounds, was used as a positive control (Figure S19). 
The cobalt(III)-cyclam complex, 1 exhibited greater potency 
(4-fold lower IC50 value, p < 0.05, n = 18, statistically 
significant) for CSC-enriched HMLER-shEcad cells than 
CSC-depleted HMLER cells. Notably, the IC50 value of 1 
towards HMLER-shEcad cells was 46-fold lower than that 
of salinomycin. The potency and selectivity of 1 towards 
HMLER-shEcad cells was better than that of a recently 
reported series of copper(II)-phenanthroline complexes 
containing indomethacin.[10a] Naproxen and 2 were 
relatively non-toxic (IC50 > 100 μM) towards both cell lines. 
The discrepancy in cytotoxicity of 1 and its components, 
naproxen and 2, might be due to a difference in cell uptake. 
To support this suggestion, cellular uptake studies were 
performed to investigate the CSC permeability and 
intracellular localisation of 1 and 2. HMLER-shEcad cells 
were incubated with 1 and 2 (0.5 µM for 12 h) and the 
cobalt content was determined in the nuclear, cytoplasmic, 
membrane, and whole cell fractions using inductively 
coupled plasma mass spectrometry (ICP-MS) (Figure 1). 
The whole cell uptake of 1 (321.1 ± 10.0 ppb of Co/ million 
cells) was 24-fold greater than 2 (13.2 ± 0.2 ppb of Co/ 
million cells). Therefore the variance in cytotoxicity of 1 and 
2 could indeed be related to their contrasting cellular 
uptake. An appreciable amount of internalised 1 was 
detected in the nucleus (42.0 ± 0.4 ppb of Co/ million cells). 
Relatively little 2 was able to penetrate the nucleus (3.3 ± 
          
 
 
 
 
0.1 ppb of Co/ million cells). This is consistent with 
presence of naproxen moieties in 1 and not in 2, as 
naproxen is well-known to target and inhibit COX-2 which is 
concentrated on the nuclear envelope.[17]   
 
Table 1. IC50 values of the 1 and salinomycin against HMLER cells, HMLER-
shEcad cells HMLER-shEcad mammospheres. 
Compound HMLER 
IC50 [μM][a] 
HMLER-shEcad 
IC50 [μM][a] 
Mammosphere 
IC50 [μM][b] 
1 0.43 ± 0.05 0.11 ± 0.03 0.98 ± 0.02 
salinomycin 12.17 ± 3.16 5.06 ± 1.45 14.05 ± 1.58 
[a] Determined after 72 h incubation (mean of three independent experiments 
± SD). [b] Determined after 120 h incubation (mean of three independent 
experiments ± SD). 
 
Figure 1. Cobalt content in whole cell, cytoplasm, nucleus, and 
membrane fractions isolated from HMLER-shEcad cells treated with 1 
and 2 (0.5 μM for 12 h). 
 
 In non-adherent, serum-free cell cultures, breast CSCs 
can form three-dimensional tumor-like structures called 
mammospheres.[18] The ability of a given compound to 
inhibit the formation of mammospheres from single cell 
suspensions is a good indicator of CSC potency. Single cell 
suspensions of CSC-enriched HMLER-shEcad cells were 
treated with 1, 2, naproxen, and salinomycin (at their 
respective IC20 values, 5 days) and their ability to form 
mammospheres was determined using an inverted 
microscope. Upon incubation with 1, the number of 
mammospheres formed decreased markedly (65% 
reduction) compared to the untreated control (p < 0.01, 
Figure 2A). Notably, 1-treatment reduced the number of 
mammospheres formed to a greater extent than 
salinomycin (16% better reduction). The size of the 
mammospheres formed after dosage with 1 also decreased 
(Figure 2B). A similar decrease in mammosphere size was 
observed for salinomycin (Figure 2B). Naproxen- and 2-
treatment did not significantly affect the number or size of 
mammospheres formed (Figure 2A and S20). In order to 
determine the ability of 1, 2, naproxen, and salinomycin to 
reduce mammosphere viability, the colorimetric resazurin-
based reagent, TOX8 was used (Figure S21 and Table S3). 
Identical studies were also performed with clinically used 
breast cancer drugs; vinorelbine, cisplatin, and paclitaxel. It 
should be noted that cisplatin is usually used to treat 
specific types of breast cancer such as triple negative or 
BRAC gene-related breast cancer as part of a clinical 
trial.[19] The IC50 value (concentration required to reduce 
mammosphere viability by 50%) of 1 was in the micromolar 
range. Strikingly, 1 exhibited better mammosphere-potency 
than salinomycin (14-fold), vinorelbine (23-fold), and 
cisplatin (8-fold). Naproxen and paclitaxel did not display 
any observable mammosphere-potency (IC50 > 66 μM). The 
latter is consistent with a previously reported study which 
showed paclitaxel to stimulate, rather than inhibit, 
mammosphere formation.[16] A recent study showed that 
mammosphere growth (from single cell suspensions of 
HMLER cells) is promoted by hypoxia, in a HIF1α-
dependent manner.[20] The potency of 1 towards 
mammospheres grown in the presence of cobalt chloride (5 
μM), a hypoxia-mimicking agent which stabilizes HIF1α, 
increased noticeably (Figure S22). Therefore, 1 displays 
selective potency towards CSCs grown in hypoxic-like 
conditions. Under these conditions, 1-treatment (at the IC20 
value, 5 days) significantly reduced the number and size of 
mammospheres formed (Figure S23-24).  
 To gain insight into the possible mechanism of action of 
1 we utilized a well-established RNAi-based mechanism of 
action prediction methodology.[21] This methodology uses 
eight cancer cell lines, each harbouring a partial population 
of distinct GFP-tagged short hairpin RNAs (shRNAs) that 
target different genes involved in cell death signalling. 
When the cell lines are treated with a cytotoxic compound 
at equipotent doses, the hairpins enrich or deplete in a 
pattern characteristic of the mechanism of action of that 
compound. For new compounds, the pattern of hairpin 
responses (or signature) can be quantitative compared to a 
reference set of compounds with known mechanisms of 
action using a modified K-NN algorithm. Therefore we can 
confidently determine if a given compound belongs to a 
class in the reference set or a new category that is not 
represented in the reference set. The reference set includes 
all classes of clinically used cytotoxic agents, several 
targeted therapeutics, and some metal-based anticancer 
agents. Interestingly, 1 classified as a 
transcription/translation inhibitor (p-value = 0.05), indicating 
that its mechanism of action is most similar to compounds 
such as actinomycin D and puromycin (Figure 2C and S25). 
In addition to the mechanism of action classification via the 
K-NN algorithm, one can examine individual hairpin 
behaviour to glean other aspects of the mechanism of 
action.  For instance, shChk2 enrichment is an indicator of 
DNA damage.  In the reference set, DNA damaging agents 
have an average shChk2 log2(RI) value of 4.21 ± 0.69 
compared to 0.36 ± 0.46 for non-DNA damaging agents.  
Notably, 1 has a Chk2 log2(RI) value of 0.87 ± 0.35 which 
is significantly higher than other non-DNA damage agents 
(p < 0.05, Mann-Whitney U-test). Taken together, this 
suggests that 1 is perhaps able to modify DNA in a manner 
that prevents transcription or translation, and this 
contributes to its cytotoxic effect. 
 Given the high nuclease activity observed for 1 in cell-
free systems, the reasonable accumulation of 1 in the 
nucleus, and the RNAi mechanism prediction, 
immunoblotting studies were conducted to monitor the 
expression of biomarkers associated to the genomic DNA 
damage pathway. Specifically, the levels of the 
phosphorylated forms of histone H2AX (γH2AX) and Chk2 
protein kinase, both of which increase due to activation of 
the apical kinases ATM and ATR after genomic DNA 
damage, were studied.[22] HMLER-shEcad cells treated with 
1 (0.125-0.5 µM for 72 h) displayed a noticeable increase in 
the expression of γH2AX and phosphorylated Chk2, 
indicative of DNA damage (Figure S26). Unrepaired DNA 
lesions can lead to apoptosis.[23] HMLER-shEcad cells 
dosed with 1 (0.125-0.5 µM for 72 h) exhibited higher levels 
of cleaved caspase 3 and 7 compared to untreated cells 
(Figure S26), characteristic of caspase-dependent 
          
 
 
 
 
apoptosis. Overall the immunoblotting studies show that 1 
induces genomic DNA damage which culminates in 
apoptotic CSC death. 
  
 
Figure 2. A) Quantification of mammosphere formation with HMLER-
shEcad cells untreated and treated with 1, 2, naproxen, and salinomycin 
(at their IC20 values, 5 days). Error bars represent standard deviations 
and Student t test, ** = p < 0.01 and * = p < 0.05. B) Representative 
bright-field images (× 10) of HMLER-shEcad mammospheres in the 
absence and presence of 1 and salinomycin, after 5 days incubation. C) 
RNAi signature derived from the treatment of Eμ-Mycp19arf−/− lymphoma 
cells with 1 at the LD80−90 concentration.  
 
Studies have found that COX-2 is aberrantly expressed in 
breast carcinomas.[24] Raised levels of COX-2 correlate with 
poor prognostic markers such as large tumor size and high 
tumor grade.[25] COX-2 also regulates CSCs and enhance 
CSC-like characteristic such as stemness, invasiveness, 
and tumorospheres formation.[9c,9f,26] The in vitro COX-2 
inhibitory effect of 1 and naproxen was assessed using an 
enzyme immunoassay (EIA) (Figure S27). Upon incubation 
of COX-2 with 1 (0.5 µM and 5 µM), the conversion of 
arachidonic acid to PG was significantly reduced (p < 0.01, 
51-64%) compared to control samples displaying 100% 
COX-2 activity. Naproxen inhibited COX-2 activity 
marginally better than 1 (the fact that 1 contains two 
naproxen groups per compound was taken into account). 
The data shows that the COX-2 inhibitory effect of 
naproxen is retained by 1. Next, we investigated whether 
the cytotoxic mechanism of action of 1 involved COX-2 
inhibition. HMLER-shEcad cells pre-treated with 
lipopolysaccharide (LPS) (2.5 µM for 24 h), to increase 
basal COX-2 levels, were treated with 1 (0.1-0.4 µM for 72 
h) and the COX-2 expression was determined by 
immunoblotting (Figure 3A). Similar studies were also 
performed with 2 (20 µM for 72 h) and naproxen (20 µM for 
72 h) (Figure 3A). COX-2 expression decreased in the 
presence of 1 in a concentration dependent manner. As 
expected, naproxen-treatment markedly reduced COX-2 
expression. There was no observable change in COX-2 
expression upon treatment with 2. COX-2 levels were 
further analysed by flow cytometry using an Alexa Fluor® 
488 nm labelled anti-COX-2 antibody (Figure S28). Upon 
treatment of HMLER-shEcad cells (pre-treated with LPS, 
2.5 µM for 24 h) with 1 (0.5-2 µM for 48 h) a slight decrease 
in COX-2 expression was observed at the highest 
concentration tested. Complementary to the immunoblotting 
results, naproxen-treatment (20 µM for 48 h) downregulated 
COX-2 expression whereas 2-treatment (20 µM for 48 h) 
did not. Collectively, the immunobloting and flow cytometric 
data suggests that the cytotoxic effect of 1 may involve 
COX-2 inhibition. To discern if 1 evokes COX-2-dependent 
CSC death, cytotoxicity studies were performed with 
HMLER-shEcad and HMLER cells in the presence and 
absence of prostaglandin E2 (PGE2) (20 μM, 72 h), the 
product of COX-2-mediated arachidonic acid metabolism. 
The potency of 1 towards HMLER-shEcad cells decreased 
significantly in the presence of PGE2 (4.8-fold, p < 0.05) 
(Figure 3B), suggesting that 1 induces COX-2-dependent 
CSC death. As the potency of 1 towards CSC-depleted, 
COX-2 deficient HMLER cells13 remained largely unaltered 
in the presence of PGE2 (Figure 3B), the CSC-selective 
toxicity observed for 1 (Table 1, vide supra) may be due to 
its ability to induce CSC death through a COX-2-dependent 
pathway. 
 
 
Figure 3. A) COX-2 expression in HMLER-shEcad cells pre-treated with 
lipopolysaccharide (LPS) (2.5 µM for 24 h), followed by treatment with 1 
(0.1, 0.2, and 0.4 μM), naproxen (20 μM), or 2 (20 μM) after 72 h 
incubation. Whole cell lysates were resolved by SDS-PAGE and 
analyzed by immunoblotting against COX-2 and β-actin (loading control). 
B) Graphical representation of the IC50 values of 1 against HMLER and 
HMLER-shEcad cells in the absence and presence of PGE2 (20 μM). 
Error bars represent standard deviations and Student t-test, * = p < 0.05. 
   
 In summary, we present a cobalt(III)-cyclam complex, 1 
capable of selectively killing breast CSCs over bulk breast 
cancer cells and reducing mammosphere formation. 
Mechanistic studies suggest that genomic DNA damage 
and COX-2 inhibition may be involved in the cytotoxic 
mechanism of action of 1. Remarkably, the mammosphere-
potency of 1 was enhanced in hypoxia-mimicking 
conditions. The findings presented in this study could pave 
the way for the development of new, therapeutically 
relevant, metal-NSAIDs conjugates that can induce CSC 
death through multiple pathways.  
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COMMUNICATION 
Cancer stem cells fall for the 
cobait:  Compounds that show 
cancer stem cell (CSC) specific 
potency are of contemporary 
interest given the large body of 
evidence linking CSCs to tumour 
relapse. Here we present a 
cobalt(III)-cyclam complex bearing 
two naproxen moieties that is 
capable of potently and selectively 
killing breast CSCs, both in 
monolayer and three-dimensional 
cell cultures. The complex induces 
its cytotoxic effect by damaging 
genomic DNA and inhibiting COX-2 
activity. 
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